Cannabis Science subsidiary takes majority stake in German life sciences firm aimed at developing rapid HIV test

|About: Cannabis Science, Inc. (CBIS)|By:, SA News Editor

Straying from its core mission of developing cannabinoid-based therapies to improve patients' lives, Cannabis Science (OTCPK:CBIS -1.6%) subsidiary Cannabis Science Europe GmbH acquires a 74.9% stake in Bad Honnef, Germany-based Jinvator Bio Med GmbH. The immediate goal is to develop an ultra-sensitive rapid HIV/AIDS test. The company says the test, called nanoGold, can detect a single virus in blood or saliva with a 10,000-fold dilution.

Financial terms are not disclosed.